EcoDrugPlus

Purinergic Receptor P2y1

Ensembl ID : ENSAMXG00000025296
Gene Symbol: P2RY1
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSAMXG00000040207
Gene Symbol: P2RY2
3 Cross references
200 Possible Orthologues:

Putative Transcription Factor P65 Homolog

Ensembl ID : ENSAMXG00000021617
Gene Symbol: LOC103032041
3 Cross references
201 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSAMXG00000025369
Gene Symbol: P2RY4
4 Cross references
168 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSAMXG00000026325
Gene Symbol: P2RY6
2 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSAMXG00000037528
Gene Symbol: RAMP1
4 Cross references
191 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSAMXG00000016394
Gene Symbol: RIPK1
3 Cross references
198 Possible Orthologues:

Receptor-Type Tyrosine-Protein Phosphatase Beta

Ensembl ID : ENSAMXG00000024321
Gene Symbol: LOC103042836
3 Cross references
194 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSAMXG00000006530
Gene Symbol: RPTOR
1 Cross references
214 Possible Orthologues:

Renin

Ensembl ID : ENSAMXG00000012922
Gene Symbol: LOC103036504
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSAMXG00000004705
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-B

Ensembl ID : ENSAMXG00000007750
Gene Symbol: LOC103046247
3 Cross references
182 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).